Form 4: Summit Therapeutics Co-CEO Boosts Stake

Summit Therapeutics Co-Chief Executive Officer Mahkam Zanganeh reported significant purchases of common stock, increasing her beneficial ownership.

Summary

• Mahkam Zanganeh, Co-Chief Executive Officer, Director, and 10% Owner of Summit Therapeutics Inc. (SMMT), reported two purchases of common stock.
• On September 10, 2025, 333,394 shares were acquired at a weighted average price of $17.68 per share, with prices ranging from $17.49 to $17.89.
• On September 11, 2025, an additional 5,000 shares were acquired at $18.07 per share.
• These purchases were made indirectly by her spouse.
• Following these transactions, the total reported beneficial ownership by Ms. Zanganeh (including direct and various indirect holdings, some of which she disclaims full beneficial ownership except for pecuniary interest) amounts to 591,831,532 shares of common stock.

Sentiment

Score: 8

Explanation: The significant insider buying by a key executive and major shareholder indicates strong confidence in the company's future, which is a highly positive signal for investors.

Positives

• Significant insider buying by a Co-CEO, Director, and 10% owner signals strong confidence in the company's future prospects.
• The acquisition of 338,394 shares (333,394 + 5,000) at prices between $17.49 and $18.07 demonstrates a personal investment in the company's success.

Future Outlook

This Form 4 filing does not provide specific forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Industry Context

Insider purchases, especially by high-ranking executives and significant shareholders, are often viewed by the market as a positive indicator of management's belief in the company's intrinsic value and future performance, potentially signaling confidence in upcoming developments or undervaluation relative to peers in the biotechnology sector.

Comparison to Industry Standards

• While direct comparisons to specific companies or projects are not provided in this Form 4, significant insider buying by a Co-CEO and 10% owner is generally considered a strong signal of confidence, often outperforming the average insider transaction in terms of market impact.
• Such a substantial investment by a key executive suggests a belief in the company's strategic direction and potential for growth, which can be a more compelling signal than smaller, routine insider purchases seen across the broader market.

Related Party Transactions

• The reported purchases were made indirectly by the reporting person's spouse.
• Beneficial ownership also includes shares held by the Shaun Zanganeh Irrevocable Trust, the Mahkam Zanganeh Revocable Trust, and an immediate family member, for which the reporting person disclaims beneficial ownership except for pecuniary interest.

Stakeholder Impact

• Shareholders may experience increased confidence in the company's future due to management's personal investment, potentially leading to positive stock price movement.
• Employees could perceive increased stability and belief in the company's long-term vision from leadership.

Key Dates

Recommendation

The substantial insider purchases by Mahkam Zanganeh, a Co-CEO, Director, and 10% owner, signal strong conviction in Summit Therapeutics' future performance and valuation. Such a significant investment by a key executive is a powerful indicator of internal confidence, suggesting potential for future growth or undervaluation. This action provides a compelling reason for investors to consider a 'buy' position, aligning with management's demonstrated belief in the company's prospects.

Keywords

Summit Therapeutics, SMMT, Mahkam Zanganeh, Insider Buying, Stock Purchase, Form 4, Biotechnology, Pharmaceuticals, Executive Ownership